Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. ...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as meaningful contributions from recent pro...
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co...
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16....
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal...
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr...
